518 related articles for article (PubMed ID: 34004147)
1. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ; Welsh SA; Devlin JR; Barbieri E; Knight DA; Offley S; Bjelosevic S; Costacurta M; Todorovski I; Kearney CJ; Sandow JJ; Fan Z; Blyth B; McLeod V; Vissers JHA; Pavic K; Martin BP; Gregory G; Demosthenous E; Zethoven M; Kong IY; Hawkins ED; Hogg SJ; Kelly MJ; Newbold A; Simpson KJ; Kauko O; Harvey KF; Ohlmeyer M; Westermarck J; Gray N; Gardini A; Johnstone RW
Cell; 2021 Jun; 184(12):3143-3162.e32. PubMed ID: 34004147
[TBL] [Abstract][Full Text] [Related]
2. CDK9 keeps RNA polymerase II on track.
Egloff S
Cell Mol Life Sci; 2021 Jul; 78(14):5543-5567. PubMed ID: 34146121
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional activity of positive transcription elongation factor b kinase in vivo requires the C-terminal domain of RNA polymerase II.
Napolitano G; Majello B; Licciardo P; Giordano A; Lania L
Gene; 2000 Aug; 254(1-2):139-45. PubMed ID: 10974544
[TBL] [Abstract][Full Text] [Related]
4. The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.
Paparidis NF; Durvale MC; Canduri F
Mol Biosyst; 2017 Jan; 13(2):246-276. PubMed ID: 27833949
[TBL] [Abstract][Full Text] [Related]
5. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
Dow EC; Liu H; Rice AP
J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
[TBL] [Abstract][Full Text] [Related]
6. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
7. CDK9 inhibition strategy defines distinct sets of target genes.
Garriga J; Graña X
BMC Res Notes; 2014 May; 7():301. PubMed ID: 24886624
[TBL] [Abstract][Full Text] [Related]
8. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
9. Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription.
Ammosova T; Washington K; Debebe Z; Brady J; Nekhai S
Retrovirology; 2005 Jul; 2():47. PubMed ID: 16048649
[TBL] [Abstract][Full Text] [Related]
10. CDK9-dependent RNA polymerase II pausing controls transcription initiation.
Gressel S; Schwalb B; Decker TM; Qin W; Leonhardt H; Eick D; Cramer P
Elife; 2017 Oct; 6():. PubMed ID: 28994650
[TBL] [Abstract][Full Text] [Related]
11. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
Hou T; Ray S; Brasier AR
J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
[TBL] [Abstract][Full Text] [Related]
12. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.
Zhang H; Pandey S; Travers M; Sun H; Morton G; Madzo J; Chung W; Khowsathit J; Perez-Leal O; Barrero CA; Merali C; Okamoto Y; Sato T; Pan J; Garriga J; Bhanu NV; Simithy J; Patel B; Huang J; Raynal NJ; Garcia BA; Jacobson MA; Kadoch C; Merali S; Zhang Y; Childers W; Abou-Gharbia M; Karanicolas J; Baylin SB; Zahnow CA; Jelinek J; Graña X; Issa JJ
Cell; 2018 Nov; 175(5):1244-1258.e26. PubMed ID: 30454645
[TBL] [Abstract][Full Text] [Related]
13. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.
Zhou M; Halanski MA; Radonovich MF; Kashanchi F; Peng J; Price DH; Brady JN
Mol Cell Biol; 2000 Jul; 20(14):5077-86. PubMed ID: 10866664
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of Integrator-mediated transcription regulation.
Fianu I; Chen Y; Dienemann C; Dybkov O; Linden A; Urlaub H; Cramer P
Science; 2021 Nov; 374(6569):883-887. PubMed ID: 34762484
[TBL] [Abstract][Full Text] [Related]
16. The Establishment of a Hyperactive Structure Allows the Tumour Suppressor Protein p53 to Function through P-TEFb during Limited CDK9 Kinase Inhibition.
Albert TK; Antrecht C; Kremmer E; Meisterernst M
PLoS One; 2016; 11(1):e0146648. PubMed ID: 26745862
[TBL] [Abstract][Full Text] [Related]
17. Integrator Recruits Protein Phosphatase 2A to Prevent Pause Release and Facilitate Transcription Termination.
Huang KL; Jee D; Stein CB; Elrod ND; Henriques T; Mascibroda LG; Baillat D; Russell WK; Adelman K; Wagner EJ
Mol Cell; 2020 Oct; 80(2):345-358.e9. PubMed ID: 32966759
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 9 links RNA polymerase II transcription to processing of ribosomal RNA.
Burger K; Mühl B; Rohrmoser M; Coordes B; Heidemann M; Kellner M; Gruber-Eber A; Heissmeyer V; Strässer K; Eick D
J Biol Chem; 2013 Jul; 288(29):21173-21183. PubMed ID: 23744076
[TBL] [Abstract][Full Text] [Related]
19. A Cdk9-PP1 switch regulates the elongation-termination transition of RNA polymerase II.
Parua PK; Booth GT; Sansó M; Benjamin B; Tanny JC; Lis JT; Fisher RP
Nature; 2018 Jun; 558(7710):460-464. PubMed ID: 29899453
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades.
Sano M; Schneider MD
Circ Res; 2004 Oct; 95(9):867-76. PubMed ID: 15514168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
